According to GlobalData’s medical device pipeline database, 338 Cardiac Marker Tests devices are in various stages of development globally. GlobalData’s report Cardiac Marker Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 109 are in active development, while the remaining 230 are in an inactive stage of development. There are 52 products in the early stages of development, and the remaining 57 are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. A cardiac marker test is a biomarker test used to diagnose a cardiac disease event or predict the likelihood of cardiac disease through the measurement of Troponin, Brain Natriuretic Peptide, Creatine Kinase Myocardial Band and other target molecules. Cardiac marker tests are categorized into lab-based biomarker and point of care biomarker tests. Laboratory Tests: Any tests that require transporting of patient samples to a laboratory, including those with rapid turnaround times, are defined as laboratory or lab-based tests. For this Cardiac Marker tests model, lab-based tests include laboratory troponin tests, laboratory BNP tests, and CK-MB laboratory tests. Point Of Care Tests: Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often ‘handheld’ or may be small portable analyzers. For this Cardiac Marker tests model, POC tests include POC troponin tests, POC BNP tests, and other POC tests.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Marker Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Cardiac Marker Tests devices. Overall, most of these Cardiac Marker Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Cardiac Marker Tests include BBB Technologies, Upstream Medical Technologies, Abbott Diagnostics, China Medical Technologies, Roche Diagnostics International, Siemens Healthcare Diagnostics, Ortho Clinical Diagnostics, Cavadis, Beckman Coulter and Corgenix Medical.
For a complete picture of the developmental pipeline for Cardiac Marker Tests devices, buy the report here.